Abstract  Description  Claims  Drawing  Search report  Cited references 

WO2010072900A   [0008]  [0035]  [0137] 
WO2014047350A   [0010] 
WO2014036412A   [0010] 
US20150086541A   [0011] 

A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo   [0153] 
An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy   [0153] 
The hallmarks of cancer   [0153] 
Treatment of cancer patients with a serotype 5/3 chimeric oncolytic adenovirus expressing GMCSF   [0153] 
Local treatment of a pleural mesothelioma tumor with ONCOS-102 induces a systemic antitumor CD8+T-cell response, prominent infiltration of CD8+lymphocytes and Th1 type polarization   [0153] 
Phase I study with ONCOS-102 for the treatment of solid tumors - an evaluation of clinical response and exploratory analyses of immune markers   [0153] 
Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients   [0153] 
Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK   [0153] 
Oncolytic adenovirus and doxorubicin-based chemotherapy results in synergistic antitumor activity against soft-tissue sarcoma   [0153] 
Repeated intratumoral administration of ONCOS-102 leads to systemic antitumor CD8+ T-cell response and robust cellular and transcriptional immune activation at tumor site in a patient with ovarian cancer   [0153]